Hedgehog Pathway Inhibition

Aleksandar D Sekulic, Daniel Von Hoff

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

Original languageEnglish (US)
Pages (from-to)831
Number of pages1
JournalCell
Volume164
Issue number5
DOIs
StatePublished - Feb 25 2016

Fingerprint

HhAntag691
Basal Cell Carcinoma
Cells
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hedgehog Pathway Inhibition. / Sekulic, Aleksandar D; Von Hoff, Daniel.

In: Cell, Vol. 164, No. 5, 25.02.2016, p. 831.

Research output: Contribution to journalArticle

Sekulic, Aleksandar D ; Von Hoff, Daniel. / Hedgehog Pathway Inhibition. In: Cell. 2016 ; Vol. 164, No. 5. pp. 831.
@article{96785cbec1c044809faae5a21f763855,
title = "Hedgehog Pathway Inhibition",
abstract = "The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).",
author = "Sekulic, {Aleksandar D} and {Von Hoff}, Daniel",
year = "2016",
month = "2",
day = "25",
doi = "10.1016/j.cell.2016.02.021",
language = "English (US)",
volume = "164",
pages = "831",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Hedgehog Pathway Inhibition

AU - Sekulic, Aleksandar D

AU - Von Hoff, Daniel

PY - 2016/2/25

Y1 - 2016/2/25

N2 - The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

AB - The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

UR - http://www.scopus.com/inward/record.url?scp=84959421964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959421964&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2016.02.021

DO - 10.1016/j.cell.2016.02.021

M3 - Article

C2 - 26919418

AN - SCOPUS:84959421964

VL - 164

SP - 831

JO - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -